ANGPT2 and ovarian carcinoma: To our knowledge, this is the first study in which a panel of VEGFs and their receptors and Ang-1 and Ang-2 levels are quantified from the serum samples of the same patient population and correlated with the diagnosis and clinical outcomes of ovarian carcinoma patients.